NPI-001
AssetAlso AT-001, NACA
Replenishes intracellular glutathione to reduce oxidative stress and protect retinal photoreceptors.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 7
- Indications
- 3
- Trials
- 2
- Developers
Indications
7Retinitis pigmentosa
Phase 3, Recruiting, NCT07710196, clinicaltrials.gov, 16 Oct 2026
Usher syndrome
Phase 3, Recruiting, NCT07710196, clinicaltrials.gov, 16 Oct 2026
Alzheimer's disease
Phase 2, arctictherapeutics.com, 10 Oct 2026
4 more
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials3
- Evidence for its targets1
- Competitors12
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.